Opinion

Video

AYA ALL: Role of Asparaginase Erwinia Chrysanthemi

Author(s):

Michael R. Grunwald, MD, FACP,Kelly Weaver, NP, DNP

Grace Elsey, PharmD, discusses the trial that led to the approval of asparaginase erwinia chrysanthemi and how it impacts AYA ALL treatment paradigms.

Video content above is prompted by the following questions:

  • Please comment on the trial led to the approval of use for asparaginase erwinia chrysanthemi in AYA ALL.
    • How does for asparaginase erwinia chrysanthemi work?
    • What are your thoughts on the key efficacy outcomes?
Related Videos
Michael R. Grunwald, MD, FACP
Minoo Battiwalla, MD, MS
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
November 15th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

Jubilee Brown, MD, professor, director, Gynecologic Oncology, Atrium Health Levine Cancer Institute
May 13th 2024

Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer

FDA
November 14th 2024

FDA Approves Nilotinib Tablets Without Mealtime Restrictions for CML

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Jennifer Amengual, MD, Herbert Irving Assistant Professor of Medicine, Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center
November 13th 2024

Real-World Experience With CAR T Varies From Trials in DLBCL

Revumenib in NPM1+ R/R AML | Image Credit: © LASZLO– stock.adobe.com
November 12th 2024

Revumenib Meets CR/CRh End Point in NPM1+ R/R AML